Do you have any questions? (088) 2080369 - 2345622 Pharmacy_QAAU@pharm.aun.edu.eg
It has been decided that the midterm (coursework) exam for the Matrouh Pharmacognosy-1 course for Al-Ahliya University students will be held on Tuesday, 25/11/2025, from 10:00 AM to 11:00 AM in Hall (2) located beneath the lecture theatres.
The Practical Exam for the Pharmacognosy (2) course for Second-Year Pharm.D students will be held on Sunday, 30/11/2025, during the scheduled practical session.
Important Notice
All students must attend the exam in their assigned laboratory.
The Practical Exam for the Pharmacognosy (2) course will be held on Wednesday, 26/11/2025, during the scheduled practical session.
Important Notice
All students must attend the exam in their assigned laboratory.
Click below
?
Medicinal Plants Course Grades for First-Year Pharm.D (Clinical Pharmacy) Students
Students wishing to submit an appeal regarding the Midterm Exam grade must register their names with the Department Secretariat starting from Sunday, 16/11/2025, until Thursday, 20/11/2025.
The results of the appeal review will be announced for all students who have registered their names with the Department Secretariat.
Click below
?
Medicinal Plants Course Grades for Pharm.D Students
Students wishing to submit an appeal regarding the Midterm Exam grade must register their names with the Department Secretariat starting from Sunday, 16/11/2025, until Thursday, 20/11/2025.
The results of the appeal review will be announced for all students who have registered their names with the Department Secretariat.
God willing, the Faculty of Pharmacy council will hold its monthly meeting on Sunday, November 16, 2025 at 10:30 (AM)
in the Hall of Faculty Council, 5th floor, administrative building
God willing, the Executive Committee meeting and That will be on Sunday, November 16, 2025 at 10:00 AM. The meeting will take place in the Faculty Council Hall, 5th Floor (Administrative Building)
(Prof. Gihan Nabil Hassan Fetih)
God willing, the meeting of the Libraries Committee at the Faculty of Pharmacy Pharmacy on Sunday, November 16, 2025 at 11:00 AM at the invitation of Professor Mrs. Professor Dr. Gihan Nabil Hassan Fetih
The seminar will be held on Thursday, November 13, 2025, at 10:00 a.m. in the department’s lecture hall, covering the research projects conducted during the period from October 5, 2025, to November 13, 2025.
God is the Grantor of success.
Acute renal failure (ARF) is a sudden, significant, and often reversible decline in kidney function, with 25% of all hospital-administered pharmaceuticals potentially causing nephrotoxicity. The study investigates the effectiveness of a novel nanoparticle (NP) formulation of glutathione (GSH) and Lepidium sativum (LS) in improving therapeutic outcomes in a rat model of ARF. Sixty adult male albino rats were allocated into ten groups, comprising six rats each, for the study. ARF was created by daily gentamicin (GN) administration for seven consecutive days and various treatment protocols, including chitosan (CS) NPs, spanlastics NPs, as well as conventional, NP formulations of GSH, LS, and their respective combinations. The effect was evaluated through various tests, and properties of nanoparticles were confirmed through characterization processes. The NP compositions markedly enhanced renal function, as seen by reduced urine concentrations of albumin and glucose. Furthermore, the serum concentrations of creatinine (SCr), blood urea nitrogen (BUN), and cystatin C were decreased. Tissue concentrations of nitrite, superoxide dismutase (SOD), and malondialdehyde (MDA), as markers of oxidative stress, were enhanced by both conventional and NP formulations. Additionally, they decreased inflammatory markers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6). Histological analysis and immunohistochemical testing revealed that the combination therapy, particularly with the nanoforms, significantly decreased caspase 3 cellular immunoexpression, a sign of kidney cellular damage. The findings show that the ARF renal damage is considerably reduced when NPs containing GSH and LS are administered together. The study suggests a promising pharmacological approach for enhancing kidney regeneration and preserving renal function, potentially aiding in new therapeutic interventions for ARF treatment.
